Appropriate Source Control and Antifungal Therapy are Associated with Improved Survival in Critically Ill Surgical Patients with Intra-abdominal Candidiasis
- PMID: 31965275
- DOI: 10.1007/s00268-020-05380-x
Appropriate Source Control and Antifungal Therapy are Associated with Improved Survival in Critically Ill Surgical Patients with Intra-abdominal Candidiasis
Abstract
Background: Intra-abdominal candidiasis (IAC) is the predominant type of invasive candidiasis with high mortality in surgical intensive care patients. The purpose of this study was to investigate the impact of appropriate source control and antifungal therapy on the outcomes of critically ill surgical patients with IAC.
Methods: This was a retrospective single-center cohort study. Adult surgical patients who were admitted to the intensive care unit and diagnosed with IAC from January 1, 2003, to December 31, 2016, were enrolled. The patients' data including risk factors of IAC, infection-related information, antifungal treatment and 30-day outcomes were collected. The primary endpoint was 30-day mortality. A COX proportional hazards model was used to analyze the association between appropriate treatment and 30-day survival.
Results: A total of 82 patients were included in the analysis. Of these, 45 (54.9%) were complicated with septic shock at IAC diagnosis. Types of IAC included peritonitis (61.0%), intra-abdominal abscesses (23.2%) and biliary tract infections (15.9%). Of the included patients, 53 (64.6%) received appropriate source control and 44 (53.7%) appropriate antifungal therapy. Compared with patients with neither of these treatments, appropriate source control (HR 0.08, 95% CI 0.02-0.30; P < 0.001), appropriate antifungal therapy (HR 0.14, 95% CI 0.04-0.55; P = 0.005), and a combination of these treatments (HR 0.02, 95% CI 0.00-0.08; P < 0.001) were associated with reduced risk of death within 30 days after IAC diagnosis.
Conclusion: For critically ill surgical patients with IAC, both appropriate source control and appropriate antifungal therapy were associated with reduced risk of 30-day mortality, and the protective effects of the two appropriate treatments were additive.
Similar articles
-
Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment.PLoS One. 2016 Apr 28;11(4):e0153247. doi: 10.1371/journal.pone.0153247. eCollection 2016. PLoS One. 2016. PMID: 27123857 Free PMC article.
-
Combination of serum and peritoneal 1.3-beta-D-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study.Crit Care. 2023 Nov 30;27(1):470. doi: 10.1186/s13054-023-04761-7. Crit Care. 2023. PMID: 38037130 Free PMC article.
-
Intraabdominal candidiasis in surgical ICU patients treated with anidulafungin: A multicenter retrospective study.Rev Esp Quimioter. 2016 Feb;29(1):32-9. Epub 2016 Jan 8. Rev Esp Quimioter. 2016. PMID: 26750771
-
Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Crit Care. 2023 Nov 20;27(1):449. doi: 10.1186/s13054-023-04742-w. Crit Care. 2023. PMID: 37981676 Free PMC article. Review.
-
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts.Intensive Care Med. 2013 Dec;39(12):2092-106. doi: 10.1007/s00134-013-3109-3. Epub 2013 Oct 9. Intensive Care Med. 2013. PMID: 24105327
Cited by
-
Detection of Candida DNA in peritoneal fluids by PCR assay optimizing the diagnosis and treatment for intra-abdominal candidiasis in high-risk ICU patients: A prospective cohort study.Front Microbiol. 2023 Jan 5;13:1070688. doi: 10.3389/fmicb.2022.1070688. eCollection 2022. Front Microbiol. 2023. PMID: 36687581 Free PMC article.
-
Candidemia in ICU Patients: What Are the Real Game-Changers for Survival?J Fungi (Basel). 2025 Feb 17;11(2):152. doi: 10.3390/jof11020152. J Fungi (Basel). 2025. PMID: 39997446 Free PMC article.
-
Role of liposomal amphotericin B in intensive care unit: an expert opinion paper.J Anesth Analg Crit Care. 2025 Apr 29;5(1):23. doi: 10.1186/s44158-025-00236-z. J Anesth Analg Crit Care. 2025. PMID: 40301956 Free PMC article. Review.
-
Distribution and drug resistance analysis of pathogens in early-stage digestive tract perforation complicated with peritonitis.Sci Rep. 2025 May 19;15(1):17308. doi: 10.1038/s41598-025-02543-5. Sci Rep. 2025. PMID: 40389620 Free PMC article.
-
Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Rev Esp Quimioter. 2025 Mar 27;38(3):152-186. doi: 10.37201/req/017.2025. Rev Esp Quimioter. 2025. PMID: 40145524 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical